Mergers and acquisitions

bluebird bio
#Gene therapy #Genetic diseases #Mergers and acquisitions

bluebird bio agrees to acquisition due to “financial challenges”

bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives.  The decision was made after a third and final denial by the Food & Drug Administration (FDA) of bluebird’s appeal… Read More

#Business & Investment #News #Trending News

#Collaboration #Drug discovery #Mergers and acquisitions #Partnership

The new industry deals progressing drug discovery

New partnerships, acquisitions and collaborations are helping drug discovery companies to tackle some of the biggest problems facing the industry. These include patient access to cell and gene therapies, the development of DNA gene therapies, and the challenges surrounding GI clinical trials.  Delbert acquires injectable antibiotic from Bristol Myers Squibb… Read More

#Business & Investment #News

Novartis head office
#Anthos Therapeutics #Cardiovascular disease #Mergers and acquisitions #Monoclonal antibodies #Novartis

Novartis acquires Anthos Therapeutics for $925 million

Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway.  Abelacimab is currently in Phase III development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation.  Novartis will make an… Read More

#Business & Investment #News #Trending News

Brain Awareness Week
#Artificial intelligence (AI) #Collaboration #Mergers and acquisitions #Partnership

Seven new drug discovery deals powered by AI

1 Servier and Google Cloud Servier and Google Cloud have announced an expanded five-year partnership focused on using AI and generative AI (gen AI) to accelerate the research and development (R&D) of innovative therapeutic solutions for patients.  According to Servier, by analysing large amounts of medical data in real time,… Read More

#Business & Investment #Editor's Choice #News

#Cormica #Mergers and acquisitions

Cormia expands European operations with Zwisler acquisition

Life sciences testing and consulting company Cormica has completed the acquisition of Zwisler Laboratorium, a provider of laboratory services headquartered in Reichenau, Germany.  The acquisition marks Cormica’s first entry into the German market and the company has revealed plans to explore additional opportunities for expansion in the country.  Founded in… Read More

#Business & Investment #News

Gastrointestinal tract
#Gastrointestinal #GSK #Mergers and acquisitions #Oncology

GSK grows gastrointestinal cancers portfolio with new acquisition

GSK has revealed it will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).  Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.   The acquisition includes lead molecule, IDRX-42,… Read More

#Business & Investment #Cancer Research #News

Roche headquarters
#CAR-T #Cell therapy #Mergers and acquisitions #Poseida Therapeutics #Roche

Roche buys CAR-T specialist Poseida Therapeutics for $1.5bn

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.  Roche will acquire the company for $9 per share in cash at closing, representing a total equity value of approximately $1 billion.  Stockholders would also receive a non-tradeable contingent… Read More

#Business & Investment #News #Trending News

#Business #Collaboration #Drug discovery #Mergers and acquisitions #Partnership

Drug discovery companies partner to overcome challenges

The latest collaborations within drug discovery will focus on drug combinations, antibodies, nanovesicles, and organ-on-a-chip technology to advance the treatment of sarcopenia, and cardiovascular, kidney and genetic diseases. IsomAb and Catalent Biotechnology company IsomAb and Catalent have entered a strategic collaboration, which includes development of ISM-001 from cell line development… Read More

#Business & Investment #News

#Autoimmune disease #Cell therapy #Immuno-oncology #Kiji Therapeutics #Mergers and acquisitions #Monoclonal antibodies #REGiMMUNE #Stem cells

REGiMMUNE and Kiji Therapeutics announce intention to merge

Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Both companies have been focused on… Read More

#Business & Investment #News

#Axol Bioscience #Cell lines #iPSC #Mergers and acquisitions #Phenocell #Pluripotent stem cells

iPSC technology provider Axol Bioscience acquires Phenocell

Axol Bioscience has fully acquired Phenocell, though financial terms of the agreement were not disclosed. The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Phenocell’s offering includes human iPSC-derived sebocytes… Read More

#Business & Investment #News

MRI of the brain
#epilepsy #Longboard Pharmaceuticals #Lundbeck #Mergers and acquisitions #Neurology

Acquisition to strengthen neuroscience pipeline

Lundbeck and Longboard Pharmaceuticals have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction to date in preclinical and clinical studies, with its next-generation superagonist mechanism specifically targeting… Read More

#Business & Investment #News

Merge road sign
#AcroImmune #Immunotherapy #Mergers and acquisitions #OncoC4 #Oncology

Immunotherapy companies OncoC4 and AcroImmune to merge

Biopharmaceutical companies OncoC4 and AcroImmune, both co-founded by CEO, Yang Liu and CMO, Pan Zheng, have entered into a definitive merger agreement. Under the terms of the agreement, OncoC4 will acquire 100% of the outstanding equity interests of AcroImmune. The merger expands OncoC4’s wholly owned immunotherapy pipeline with the addition… Read More

#Business & Investment #News

T cell attacking cancer cell
#Cell therapy #Citius Pharmaceuticals #FDA #Lymphoma #Mergers and acquisitions #Oncology

Citius Oncology launches following FDA approval of Lymphir

The US Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl) for the second-line treatment of r/r cutaneous T-cell lymphoma (CTCL), making it Citius Pharma’s first product approved in the US. Lymphir is a novel immunotherapy and the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on… Read More

#Business & Investment #News #Regulatory

#Chronic pain #Grünenthal #Mergers and acquisitions #Opioids #Valinor Pharma

Grünenthal acquires Valinor Pharma for $250m

German company Grünenthal has acquired US-based Valinor Pharma along with its product Movantik (naloxegol) for approximately $250 million. Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Gross sales from the drug in the United States (US) reached over $200 million… Read More

#Business & Investment #News

#Acquisition #CatSci #Chromatography #Mergers and acquisitions

CatSci acquires chromatography provider Reach Separations

CatSci has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics. The acquisition was supported by Keensight Capital, private equity managers dedicated to pan-European Growth Buyout investments. Headquartered in the UK, and with laboratories in both the UK and France, Reach Separations specialises in chromatography… Read More

#Business & Investment #News

#Business #Mergers and acquisitions

How to get the biopharma deal you want

Dr Neela Patel, Chief Business Officer at Bonum Therapeutics, offers advice on how to negotiate a winning deal in biopharma that meets investors’, buyers' and sellers’ goals.  Business development (BD) is an essential ingredient to the success of early-stage companies, whether they plan to exit through M&A, IPO, or have other mechanisms to… Read More

#Business & Investment #Exclusive Content #Opinion